Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments.

ABSTRACT: Decades of pharmacogenetic research have revealed genetic biomarkers of clinical response to antipsychotics. Genetic variants in antipsychotic targets, dopamine and serotonin receptors in particular, and in metabolic enzymes have been associated with the efficacy and toxicity of antipsychotic treatments. However, genetic prediction of antipsychotic response based on these biomarkers is far from accurate. Despite the clinical validity of these findings, the clinical utility remains unclear. Nevertheless, genetic information on CYP metabolic enzymes responsible for the biotransformation of most commercially available antipsychotics has proven to be effective for the personalisation of clinical dosing, resulting in a reduction of induced side effects and in an increase in efficacy. However, p

SUBMITTER: Hernandez M 

PROVIDER: S-EPMC10893329 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature